282 TABLETS
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
22-06-2018
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
ACETYLSALICYLIC ACID; CAFFEINE (CAFFEINE CITRATE); CODEINE PHOSPHATE
から入手可能:
PENDOPHARM DIVISION OF PHARMASCIENCE INC
ATCコード:
N02AJ07
INN（国際名）:
CODEINE AND ACETYLSALICYLIC ACID
投薬量:
375MG; 30MG; 15MG
医薬品形態:
TABLET
構図:
ACETYLSALICYLIC ACID 375MG; CAFFEINE (CAFFEINE CITRATE) 30MG; CODEINE PHOSPHATE 15MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Narcotic (CDSA I)
治療領域:
SALICYLATES
製品概要:
Active ingredient group (AIG) number: 0301235008; AHFS:
認証ステータス:
CANCELLED POST MARKET
承認日:
2021-05-11
製品の特徴
PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
N.
282
®
ACETYLSALICYLIC ACID (375 MG), CODEINE PHOSPHATE (15 MG),
CAFFEINE (15 MG*) TABLETS
*
equivalent to 30 mg caffeine citrate
N.
292
®
ACETYLSALICYLIC ACID (375 MG), CODEINE PHOSPHATE (30 MG),
CAFFEINE (15 MG*) TABLETS
*
equivalent to 30 mg caffeine citrate
ANALGESIC
ANTIPYRETIC
PENDOPHARM, DIVISION OF PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4 DATE OF REVISION:
June 22, 2018
SUBMISSION CONTROL NO.:
214268
282
and 292
are registered trademarks of Pharmascience Inc.
_282_
_®_
_ and 292_
_®_
_ Prescribing Information _
_Page 2 of 33_
_ _
TABLE OF CONTENT
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
14
DRUG INTERACTIONS
..................................................................................................
16
DOSAGE AND ADMINISTRATION
..............................................................................
17
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 19
STORAGE AND STABILITY
.........................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 21
PART II: SCIENTIFIC INFORMATION
.......................
完全なドキュメントを読む
